Featured Research

from universities, journals, and other organizations

Radiation before surgery keeps colorectal cancer from returning, study finds

Date:
October 28, 2010
Source:
American Society for Radiation Oncology
Summary:
Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study.

Patients with cancer found at the end of the large intestine called the rectum who receive one week of radiation therapy before surgery have a 50 percent reduction in chance that their cancer will return after 10 years, according to a large, randomized study to be presented at the plenary session, Nov. 1, 2010, at the 52nd Annual Meeting of the American Society for Radiation Oncology (ASTRO).

"We believe that this short course of radiation will open a new window of opportunities in the treatment of rectal cancer," Corrie Marijnen M.D., lead author of the study and a radiation oncologist at the Leiden University Medical Center, in Leiden, Netherlands, said.

Cancer coming back to its original tumor site and surrounding area, called a local recurrence, is a major problem in the treatment of rectal cancer patients. The mesorectum is the fatty tissue near the rectum that contains blood vessels and lymph nodes. When rectal cancer recurs, it is often in these lymph nodes. Therefore, a better surgical technique called total mesorectal excision (TME) was introduced worldwide. It removes the entire mesorectum and lymph nodes and is most successful when all of the tumor and surrounding area is removed and no cancer cells remain. In this study, it was demonstrated that preoperative radiotherapy is still beneficial in these optimally operated patients.

The study involved more than 1,800 rectal cancer patients who were eligible for total mesorectal excision surgery and whose disease had spread outside of its original location but not to other parts of the body. Patients were randomly selected to receive short-term radiation before surgery or surgery alone. Researchers wanted to examine the effectiveness of adding radiation to TME surgery to control local recurrence among these patients.

Findings show that patients who underwent radiation before surgery had a significant decrease (6 percent) in their chances of local recurrence after 10 years of treatment, compared to those who had did not have radiation (11 percent).

Dr. Marijnen said, "Our study suggests that tumors in the middle rectum and stage III rectal cancer patients will most greatly benefit from receiving radiation before surgery."


Story Source:

The above story is based on materials provided by American Society for Radiation Oncology. Note: Materials may be edited for content and length.


Cite This Page:

American Society for Radiation Oncology. "Radiation before surgery keeps colorectal cancer from returning, study finds." ScienceDaily. ScienceDaily, 28 October 2010. <www.sciencedaily.com/releases/2010/10/101025133755.htm>.
American Society for Radiation Oncology. (2010, October 28). Radiation before surgery keeps colorectal cancer from returning, study finds. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2010/10/101025133755.htm
American Society for Radiation Oncology. "Radiation before surgery keeps colorectal cancer from returning, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/10/101025133755.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins